Psy Therapeutics Overview
- Year Founded
-
2016
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- (Cancelled)
- Investors
-
4
Psy Therapeutics General Information
Description
Developer of novel small molecule therapies designed to treat central nervous system disorders such as pain, Parkinson's disease, and PTSD (Post-traumatic stress disorder). The company offers brain-penetrant, well-tolerated drug candidates based on a chemistry-driven, de-risked approach, enabling patients affected by serious neurological conditions to access more effective and better-tolerated treatments.
Contact Information
Website
www.psythx.comCorporate Office
- 28 Atlantic Avenue
- Suite 222
- Boston, MA 02110
- United States
Corporate Office
- 28 Atlantic Avenue
- Suite 222
- Boston, MA 02110
- United States
Psy Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | Cancelled | Pre-Clinical Trials | ||||
| 3. Seed Round | 09-Sep-2025 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 23-Dec-2021 | $2.4M | $6.4M | Completed | Startup | |
| 1. Seed Round | 01-Oct-2019 | $4M | $4M | Completed | Startup |
Psy Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Psy Therapeutics Patents
Psy Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025245367-A1 | Inhibiting catechol-o-methyltransferase (comt) | Pending | 22-May-2024 | ||
| WO-2025010394-A2 | Monoacylglycerol lipase inhibitors and use thereof for the treatment and management of inflammatory conditions | Inactive | 06-Jul-2023 | ||
| WO-2025010394-A3 | Monoacylglycerol lipase inhibitors and use thereof for the treatment and management of inflammatory conditions | Inactive | 06-Jul-2023 | ||
| WO-2025010392-A2 | Monoacylglycerol lipase inhibitors and use thereof for the treatment of neurological disorders | Inactive | 06-Jul-2023 | ||
| WO-2025010392-A3 | Monoacylglycerol lipase inhibitors and use thereof for the treatment of neurological disorders | Inactive | 06-Jul-2023 | A61P25/08 |
Psy Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ayuh Ventures | Venture Capital | Minority | ||
| JLS Fund | Venture Capital | Minority | ||
| Palo Santo | Venture Capital | Minority | ||
| WPSS.bio | Venture Capital | Minority |
Psy Therapeutics FAQs
-
When was Psy Therapeutics founded?
Psy Therapeutics was founded in 2016.
-
Where is Psy Therapeutics headquartered?
Psy Therapeutics is headquartered in Boston, MA.
-
What industry is Psy Therapeutics in?
Psy Therapeutics’s primary industry is Drug Discovery.
-
Is Psy Therapeutics a private or public company?
Psy Therapeutics is a Private company.
-
What is Psy Therapeutics’s current revenue?
The current revenue for Psy Therapeutics is .
-
How much funding has Psy Therapeutics raised over time?
Psy Therapeutics has raised $13.2M.
-
Who are Psy Therapeutics’s investors?
Ayuh Ventures, JLS Fund, Palo Santo, and WPSS.bio have invested in Psy Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process